Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS phase II study of 2-iminobiotin in acute ischemic stroke with large vessel occlusion
NL-OMON51194Phase 2Active, not recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of 2-iminobiotin in ischemic stroke and brain infarction (6 arms), sponsored by Haaglanden Medical Centre. Primary endpoints: Short-term safety and tolerability, Adverse events and serious adverse events and 1 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
2-iminobiotin
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on NL-OMON51194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51194.